Dendreon

Dendreon is a trailblazer in the cell therapy space, having achieved the historic first FDA approval of an autologous cellular immunotherapy, Provenge, for advanced prostate cancer in 2010. The company has leveraged its deep expertise in complex, personalized cell therapy manufacturing and commercialization to build a dual-pillar business model: marketing Provenge and providing end-to-end manufacturing services as a CDMO for partners. While facing past financial challenges, Dendreon's current strategy focuses on expanding the reach of its proven therapy and capitalizing on the booming cell and gene therapy market through its specialized manufacturing capabilities.

Proprietary platform for the industrialized manufacturing of autologous cellular immunotherapies, involving leukapheresis, ex vivo activation of antigen-presenting cells with target antigen fusion proteins, and reinfusion.

In prostate cancer, Provenge competes with oral agents like enzalutamide and abiraterone, chemotherapy, and other modalities. As a CDMO, it competes with large, diversified CDMOs (Lonza, Catalent) and specialized cell therapy manufacturers, differentiating itself with its specific Provenge commercialization and regulatory experience.